Cargando…

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature

BACKGROUND: Dalbavancin is a long acting, semisynthetic derivative of teicoplanin that is currently approved for treatment of acute bacterial skin and skin structure infections. Its efficacy and role of in the treatment of invasive infections, in particular infective endocarditis, is not well known....

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazili, Tasaduq, Bansal, Ekta, de la Espriella, Mariana Gomez, Garner, Dorothy C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644484/ http://dx.doi.org/10.1093/ofid/ofab466.884

Ejemplares similares

323. First case of Prosthetic joint infection due to Nocardia veterana-elegans
por: Fazili, Tasaduq, et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

687. Iatrogenic Kaposi’s Sarcoma Following Treatment with Vedolizumab
por: Ajao, Susanne O, et al.
Publicado: (2020)

Triple Threat: Triple-Valve Endocarditis Case Report and Literature Review
por: Vattikonda, Kiriti S., et al.
Publicado: (2023)

Infectious Aortitis Due to Salmonella Species Masquerading as Lung Malignancy
por: O’Shea, John-Paul, et al.
Publicado: (2023)

923 Lactococcus garvieae infective endocarditis requiring valve replacement: First case in the United States
por: Sharngoe, Calden, et al.
Publicado: (2014)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers
por: Sader, Helio S, et al.
Publicado: (2018)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin
por: Oliva, Alessandra, et al.
Publicado: (2021)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
por: Evins, Connor, et al.
Publicado: (2022)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis
por: Teigell-Muñoz, Francisco Javier, et al.
Publicado: (2023)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
por: Bidikian, Aram, et al.
Publicado: (2023)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality
por: de Pablo-Miró, Mar, et al.
Publicado: (2021)

Configuring Windows 8: exam ref 70-687
por: Halsey, Mike, et al.
Publicado: (2013)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases
por: Hitzenbichler, Florian, et al.
Publicado: (2020)

Pott’s Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
por: Jones, Zachary, et al.
Publicado: (2017)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)
por: Sader, Helio S., et al.
Publicado: (2022)

Alterations in the molecular composition of COVID-19 patient urine, detected using Raman spectroscopic/computational analysis
por: Robertson, John L., et al.
Publicado: (2022)

Exam ref 70-687: configuring Windows 8.1
por: Ballew, Joli
Publicado: (2014)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

Post-malaria neurological syndrome: a rare neurological complication of malaria
por: Yadava, Sanjay K., et al.
Publicado: (2019)

Gram positive bacterial infections in immunocompromised patients with HIV infection
por: Stoian, Andreea Cristina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_noc82a475ahr4ttioo3u81l32a